Beta-synuclein in cerebrospinal fluid as an early diagnostic marker of Alzheimer's disease.
Steffen HalbgebauerPatrick OecklPetra SteinackerDeniz Yilmazer-HankeSarah Anderl-StraubChristine von ArnimLutz FroelichLuis Aragão GomesLucrezia HausnerAndre HussHolger JahnJochen H WeishauptAlbert C LudolphDietmar R ThalMarkus OttoPublished in: Journal of neurology, neurosurgery, and psychiatry (2020)
We successfully established a sensitive and robust ELISA for the measurement of brain-enriched beta-synuclein, which we could show is localised in glutamatergic synapses. We confirmed previous, mass spectrometry-based observations of increased beta-synuclein levels in CSF of patients with AD and CJD supporting its potential use as a marker of synaptic degeneration.